Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

GLYC

GlycoMimetics Inc

Dec 11 • 04:00PM ET

0.2804

Dollar change -0.0125
Percentage change -4.27	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE AXSM AFMD HOOK IMMP XFOR CDTX NERV PIRS SYBX

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.62	Insider Own	11.50%	Shs Outstand	64.48M	Perf Week	-6.84%
Market Cap	18.08M	Forward P/E	-	EPS next Y	-	Insider Trans	-20.81%	Shs Float	57.07M	Perf Month	-32.85%
Income	-39.74M	PEG	-	EPS next Q	-	Inst Own	42.19%	Short Float	4.55%	Perf Quarter	70.98%
Sales	0.01M	P/S	1808.00	EPS this Y	-	Inst Trans	37.55%	Short Ratio	0.13	Perf Half Y	6.62%
Book/sh	0.18	P/B	1.59	EPS next Y	-	ROA	-115.34%	Short Interest	2.60M	Perf Year	-82.69%
Cash/sh	0.22	P/C	1.26	EPS next 5Y	-	ROE	-137.20%	52W Range	0.14 - 3.53	Perf YTD	-88.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	13.11%	ROI	-349.28%	52W High	-92.06%	Beta	1.78
Dividend TTM	-	Quick Ratio	3.62	Sales past 5Y	-53.76%	Gross Margin	-484.71%	52W Low	99.43%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	3.62	EPS Y/Y TTM	3.16%	Oper. Margin	-367849.25%	RSI (14)	42.68	Volatility	10.99% 11.51%
Employees	35	Debt/Eq	0.02	Sales Y/Y TTM	-86.67%	Profit Margin	-397354.06%	Recom	3.00	Target Price	0.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-6.57%	Payout	-	Rel Volume	0.02	Prev Close	0.29
Sales Surprise	-	EPS Surprise	-6.25%	Sales Q/Q	-	Earnings	Aug 01	Avg Volume	19.65M	Price	0.28
SMA20	-15.57%	SMA50	-1.36%	SMA200	-63.99%	Trades		Volume	353,751	Change	-4.27%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-26-24	Downgrade	TD Cowen	Buy → Hold
Dec-22-23	Initiated	CapitalOne	Overweight	$12
Nov-12-21	Upgrade	Jefferies	Hold → Buy	$3 → $4
Nov-14-19	Initiated	ROTH Capital	Buy	$12
Aug-05-19	Downgrade	SunTrust	Buy → Hold	$23 → $5
Aug-05-19	Downgrade	Piper Jaffray	Overweight → Neutral	$20 → $6
Aug-05-19	Downgrade	Jefferies	Buy → Hold
Apr-12-19	Initiated	Piper Jaffray	Overweight	$20
Dec-18-18	Initiated	H.C. Wainwright	Buy	$24
Jul-26-16	Initiated	SunTrust	Buy
Mar-17-15	Reiterated	Stifel	Buy	$13 → $14

Show Previous Ratings

Nov-13-24 05:15PM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
Nov-12-24 08:00AM	Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 (PR Newswire) -5.29%
Nov-06-24 07:00AM	GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting (Business Wire)
Oct-30-24 08:31AM	GlycoMimetics Announces Merger with Crescent Biopharma (TipRanks) -6.84%
Oct-29-24 07:00AM	GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma (Business Wire) +191.32%
06:30AM	Loading…
06:30AM	GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint (Business Wire)
Jul-25-24 09:00AM	GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan (Business Wire) -24.20%
Jul-22-24 07:00AM	7 Sorry Biotech Stocks Set to Make Investors Sad (InvestorPlace) +13.89%
Jun-26-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -12.60%
Jun-25-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +25.28%
Jun-04-24 07:00AM	GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire) +7.38%
May-29-24 04:01PM	GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 (Business Wire) +6.82%
May-28-24 04:05AM	Pipeline Moves: Phase III AML trial fails to meet primary endpoint (Clinical Trials Arena)
May-09-24 10:58PM	GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024 (InvestorPlace) -10.54%
07:19PM	GlycoMimetics: Q1 Earnings Snapshot (Associated Press Finance)
07:42AM	Loading…
May-08-24 07:42AM	Uproleselans failed Phase III AML trial shakes up GlycoMimetics future (Clinical Trials Arena)
May-07-24 05:21AM	GlycoMimetics reports data from Phase III AML treatment trial (Clinical Trials Arena)
May-06-24 03:53PM	Sector Update: Health Care Stocks Higher in Late Afternoon Trading (MT Newswires) -82.76%
12:45PM	GlycoMimetics Shares Slump After Cancer Treatment Drug Combination Fails to Meet Primary Endpoint (MT Newswires)
08:40AM	Why Is GlycoMimetics (GLYC) Stock Down 77% Today? (InvestorPlace)
07:52AM	GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
06:00AM	GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) (Business Wire)
Apr-25-24 07:00AM	GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire) -7.82%
Mar-28-24 10:12AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.66%
02:10AM	Q4 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 11:53AM	GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023 (InvestorPlace) +11.58%
10:31AM	GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections (GuruFocus.com)
07:14AM	GlycoMimetics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 (Business Wire)
08:50AM	Loading…
Mar-21-24 08:50AM	Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? (Zacks) -5.57%
Mar-13-24 07:00AM	GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 (Business Wire)
Feb-26-24 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference (Business Wire) +5.52%
Feb-12-24 07:00AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.47%
Jan-04-24 07:00AM	GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687 (Business Wire)
Jan-03-24 07:00AM	Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) +11.40%
Dec-10-23 12:00PM	GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia (Business Wire)
Nov-09-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference (Business Wire) -10.45%
Nov-05-23 08:51AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-04-23 01:48AM	Q3 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-03-23 10:33AM	GlycoMimetics Inc (GLYC) Reports Q3 2023 Financial Results (GuruFocus.com)
07:07AM	GlycoMimetics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023 (Business Wire)
Oct-23-23 08:30AM	Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board (PR Newswire) -7.14%
Oct-20-23 07:00AM	GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023 (Business Wire)
Sep-06-23 07:00AM	GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687 (Business Wire)
Sep-05-23 07:00AM	GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference (Business Wire) -5.10%
Aug-17-23 07:00AM	GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-02-23 07:17AM	GlycoMimetics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023 (Business Wire)
Jul-19-23 07:00AM	GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023 (Business Wire) -6.43%
Jul-13-23 09:29AM	12 Best Multibagger Penny Stocks To Buy (Insider Monkey)
Jun-26-23 08:00AM	GlycoMimetics Announces Its Addition to the Russell Microcap® Index (Business Wire)
Jun-15-23 08:00AM	GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia (Business Wire) +8.52%
Jun-12-23 11:13AM	We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-31-23 07:00AM	GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference (Business Wire)
May-16-23 10:37AM	retail investors who own 36% along with institutions invested in GlycoMimetics, Inc. (NASDAQ:GLYC) saw increase in their holdings value last week (Simply Wall St.) -6.73%
May-03-23 10:17PM	Q1 2023 GlycoMimetics Inc Earnings Call (Thomson Reuters StreetEvents) +7.35%
07:23AM	GlycoMimetics: Q1 Earnings Snapshot (AP Finance)
07:00AM	GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023 (Business Wire)
Apr-26-23 07:00AM	GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023 (Business Wire)
Apr-19-23 10:20AM	Possible turnaround for GlycoMimetics, Inc. (NASDAQ:GLYC) insiders, still down US$63k after a US$732k shopping spree (Simply Wall St.)
Apr-05-23 01:45PM	The Quant Trading System Picking Stocks That Soar 300% (InvestorPlace)
Mar-31-23 04:30AM	GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-29-23 07:00AM	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022 (Business Wire) -9.29%
Mar-21-23 06:23AM	Daily Vickers Top Insider Picks for 03/21/2023 (Argus Research)
Mar-20-23 06:35AM	Daily Vickers Top Insider Picks for 03/20/2023 (Argus Research)
Mar-17-23 06:47AM	Daily Vickers Top Insider Picks for 03/17/2023 (Argus Research) -5.41%
Mar-16-23 07:00AM	GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023 (Business Wire)
06:51AM	Daily Vickers Top Insider Picks for 03/16/2023 (Argus Research)
Mar-15-23 06:44AM	Daily Vickers Top Insider Picks for 03/15/2023 (Argus Research)
Mar-13-23 06:32AM	Daily Vickers Top Insider Picks for 03/13/2023 (Argus Research) +10.69%
Mar-10-23 07:04AM	Daily Vickers Top Insider Picks for 03/10/2023 (Argus Research)
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research) -9.52%
Mar-08-23 06:30AM	Daily Vickers Top Insider Picks for 03/08/2023 (Argus Research)
Mar-07-23 06:34AM	Daily Vickers Top Insider Picks for 03/07/2023 (Argus Research)
Mar-06-23 07:22AM	Daily Vickers Top Insider Picks for 03/06/2023 (Argus Research) -5.13%
Mar-03-23 06:38AM	Daily Vickers Top Insider Picks for 03/03/2023 (Argus Research)
Mar-02-23 06:44AM	Daily Vickers Top Insider Picks for 03/02/2023 (Argus Research)
Mar-01-23 07:00AM	GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference (Business Wire)
06:01AM	Daily Vickers Top Insider Picks for 03/01/2023 (Argus Research)
06:01AM	Daily Vickers Top Buyers & Sellers for 03/01/2023 (Argus Research)
Feb-28-23 06:43AM	Daily Vickers Top Insider Picks for 02/28/2023 (Argus Research)
Feb-27-23 06:50AM	Daily Vickers Top Insider Picks for 02/27/2023 (Argus Research)
Feb-24-23 07:17AM	Daily Vickers Top Insider Picks for 02/24/2023 (Argus Research)
07:17AM	Daily Vickers Top Buyers & Sellers for 02/24/2023 (Argus Research)
Feb-16-23 08:00AM	GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +19.41%
Feb-15-23 08:00AM	GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee (Business Wire) -62.47%
Feb-14-23 06:23AM	Daily Vickers Top Buyers & Sellers for 02/14/2023 (Argus Research) +7.14%
Feb-06-23 07:00AM	GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jan-22-23 07:30AM	This Small Pharma Company Could Develop Into a Nice Trade (TheStreet.com)
07:24AM	GlycoMimetics, Inc.'s (NASDAQ:GLYC) Shift From Loss To Profit (Simply Wall St.)
Dec-30-22 07:17AM	Daily Vickers Top Insider Picks for 12/30/2022 (Argus Research)
Dec-28-22 06:58AM	Daily Vickers Top Buyers & Sellers for 12/28/2022 (Argus Research) +19.20%
Dec-26-22 07:14AM	Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-19-22 09:40AM	Is Axonics (AXNX) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-12-22 07:00AM	GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting (Business Wire)
Dec-02-22 01:18PM	Individual investors account for 44% of GlycoMimetics, Inc.'s (NASDAQ:GLYC) ownership, while hedge funds account for 18% (Simply Wall St.) +7.01%
09:40AM	Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-23-22 09:55AM	After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright (Zacks)

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Invus Public Equities, L.P.	10% Owner	Aug 08 '24	Sale	0.19	260,873	50,009	6,317,565	Aug 09 04:30 PM
Invus Public Equities, L.P.	10% Owner	Aug 07 '24	Sale	0.18	61,488	11,197	6,578,438	Aug 09 04:30 PM
Invus Public Equities, L.P.	10% Owner	Aug 05 '24	Sale	0.19	164,523	30,996	6,695,658	Aug 07 04:30 PM
Invus Public Equities, L.P.	10% Owner	Aug 06 '24	Sale	0.18	55,732	10,188	6,639,926	Aug 07 04:30 PM
Invus Public Equities, L.P.	10% Owner	Aug 02 '24	Sale	0.20	286,200	57,354	6,860,181	Aug 05 04:53 PM
Invus Public Equities, L.P.	10% Owner	Aug 01 '24	Sale	0.22	63,564	13,743	7,146,381	Aug 05 04:53 PM
Invus Public Equities, L.P.	10% Owner	Jul 30 '24	Sale	0.22	756,835	167,185	7,209,945	Jul 30 05:16 PM
Invus Public Equities, L.P.	10% Owner	Jul 29 '24	Sale	0.24	363,949	85,637	7,966,780	Jul 30 05:16 PM
Invus Public Equities, L.P.	10% Owner	Jul 26 '24	Sale	0.24	258,335	62,440	8,330,729	Jul 30 05:16 PM
Rock Edwin	Chief Medical Officer	Jun 20 '24	Buy	0.25	190,000	48,108	565,403	Jun 24 04:29 PM
Rock Edwin	Chief Medical Officer	Jun 21 '24	Buy	0.27	115,000	30,716	680,403	Jun 24 04:29 PM
Hahn Brian M.	SVP Finance, CFO	Jun 18 '24	Buy	0.25	17,500	4,335	70,643	Jun 20 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GLYC

GlycoMimetics Inc

Upgrade your FINVIZ experience